Typical Weight Loss on Ozempic
Clinical trials show patients on Ozempic (semaglutide 2.4 mg weekly, the dose studied for weight loss) lose 15-20% of body weight over 68 weeks, averaging about 15% or 35 pounds for someone starting at 230 pounds. This comes from the STEP trials, where 83% of participants lost at least 5% body weight and over half lost 10% or more.[1][2]
Lower doses approved for diabetes (0.5-1 mg weekly) produce less weight loss, around 5-10% over a year.[3]
How Long Until You See Results?
Weight loss starts within 4-12 weeks, with most gains by 20 weeks. Plateau often hits after 60-68 weeks; continuing beyond that yields minimal extra loss.[1][4]
Factors Affecting Weight Loss Amounts
- Starting weight: Heavier patients lose more absolute pounds.
- Dose and adherence: Higher doses and consistent injections maximize results.
- Diet and exercise: Trials paired it with 500-calorie daily deficit and activity; real-world use without these sees 8-12% loss.[5]
- Demographics: Women and those with higher BMI respond better on average.[2]
What If You Stop Ozempic?
Most regain two-thirds of lost weight within a year off the drug, due to slowed metabolism and appetite rebound. Trials restarting semaglutide after a break recaptured much of the loss.[6]
Ozempic vs. Wegovy for Weight Loss
Wegovy is the same drug (semaglutide) at the 2.4 mg dose, FDA-approved specifically for weight management, while Ozempic is for diabetes but used off-label for weight. Results match: 15-17% loss. Shortages have pushed Ozempic use for obesity.[7]
Common Side Effects Tied to Weight Loss
Nausea (44%), diarrhea (30%), and vomiting (25%) peak early and drive initial rapid loss, but fade over time. These affect 70% of users and lead to 7% dropout in trials.[1][3] Gallbladder issues and pancreatitis risks rise with rapid loss.
Real-World Results vs. Trials
Outside trials, average loss is 10-15% at one year, lower due to inconsistent use or lower doses. Patient forums report 20-50 pounds in 6 months for many, but 20-30% see under 10%.[5][8]
[1]: NEJM: STEP 1 Trial
[2]: Novo Nordisk STEP Program Data
[3]: FDA Ozempic Label
[4]: JAMA: Semaglutide Timeline Analysis
[5]: Health Affairs: Real-World Weight Loss Study
[6]: NEJM: STEP 1 Extension
[7]: FDA: Wegovy Approval
[8]: DrugPatentWatch: Semaglutide Overview